Glucagon-like peptide-1 (GLP-1) is a 30- or 31-amino-acid-long peptide hormone deriving from tissue-specific posttranslational processing of the proglucagon peptide.
Apr 8, 2026 ·The development of glucagon-like peptide1(GLP1) receptor agonists, including semaglutide and tirzepatide, has transformed the clinical management of overweight and obesity.
Apr 8, 2026 ·This new report includes an interactive tool that allows individuals to explore how genetics and otherfactorslike age and certain medical conditions mayimpactweightlossand nausea onGLP-1...
Jun1, 2025 ·Abstract Glucagon-like peptide-1(GLP-1) receptor agonists (RAs) have become central in managing obesity and type 2 diabetes, primarily through appetite suppression and metabolic regulation. This review explores the mechanisms underlyingGLP-1RA-inducedweightloss, focusing on central and peripheral pathways.
In recent years, glucagon-like peptide-1(GLP-1) receptor agonists have gained widespread popularity not only as effective agents in the management of type 2 diabetes but also for their beneficialimpacton weightloss.
Feb 5, 2026 ·Everything you need to know aboutGLP-1s forweightlossFrom semaglutide to tirzepatide, this article collates the latest information on pharmacologicalweight-losstreatments, including evidence and best practice for their use.
Oct 30, 2025 ·GLP-1drugs show promise forweightmanagement Across the reviews, tirzepatide, semaglutide, and liraglutide each led to significantweightlosscompared to placebo after one to two years, with these effects likely to be sustained while treatment continues.
Jan 31, 2026 ·Genes affect how well semaglutide (Ozympic) and tirzepatide work. Check yourGLP-1receptor gene variants linked toweightlossresponse. Genotype report included.
.png?format=2500w "Understanding GLP-1: The Hormone Behind Effective Weight Loss ...")
